Pediatric non alcoholic fatty liver disease: More on novel treatment targets

BMC Pediatrics

Volumn 13, Issue 1, 2013, Pages

  Vajro, Pietro ^a   Paolella, Giulia ^a   Poeta, Marco ^a   Pizza, Cristina ^a   Sangermano, Maria ^a   Massa, Grazia ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Children; Gut liver axis; Microbiota; Non alcoholic fatty liver disease; Probiotics; Therapy

Indexed keywords

AMINOTRANSFERASE; PROBIOTIC AGENT;

APOPTOSIS; DIET THERAPY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; INSULIN RESISTANCE; INTESTINE; INTESTINE FLORA; LIFESTYLE MODIFICATION; LIVER; LIVER BIOPSY; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; NOTE; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); CHILD; FATTY LIVER; LIFESTYLE; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY;

CHILD; COMBINED MODALITY THERAPY; FATTY LIVER; HUMANS; LIFE STYLE; NON-ALCOHOLIC FATTY LIVER DISEASE; PROBIOTICS;

EID: 84880335446     PISSN: None     EISSN: 14712431     Source Type: Journal    
DOI: 10.1186/1471-2431-13-109     Document Type: Note

References (8)

1. Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013, in press.
2. Esposito E, Iacono A, Bianco G, Autore G, Cuzzocrea S, Vajro P, Canani RB, Calignano A, Raso GM, Meli R. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009, 139:905-911. 10.3945/jn.108.101808, 19321579.
3. Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: a mini-review on their influences on obesity and obesity related liver disease. J Pediatr Gastroenterol Nutr 2013, 56:461-468. 10.1097/MPG.0b013e318284abb5, 23287807.
4. Vajro P, Lenta S, Pignata C, Salerno M, D'Aniello R, De Micco I, Paolella G, Parenti G. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr 2012, 38:55. 10.1186/1824-7288-38-55, 3534557, 23075296.
5. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007, CD005165.
6. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 2011, 15:1090-1095.
7. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Vallone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011, 52:740-743. 10.1097/MPG.0b013e31821f9b85, 21505361.
8. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012, 46:272-284. 10.1097/MCG.0b013e31824587e0, 22395062.